市场调查报告书
商品编码
1322030
全球心臟再同步治疗 (CRT) 市场(2023-2030):按类型、应用(心室内异步、心室间异步)和最终用户划分的规模、份额、增长分析和预测Global Cardiac Resynchronization Therapy Market Size, Share, Growth Analysis, By Type, By Application(Intraventricular desynchrony, Interventricular desynchrony), By End User - Industry Forecast 2023-2030 |
全球心臟再同步治疗 (CRT) 市场规模预计将从 2021 年的 40.6 亿美元增长到 2022 年的 42.6 亿美元,预测期内復合年增长率为 4.8%,到 2030 年预计还将增长2019年达到62.3亿美元。
CRT 是一种治疗心力衰竭患者的方法。 由于全球心血管疾病患病率不断上升,全球 CRT 市场正在显着增长。 CRT 设备有助于恢復同步心臟收缩并改善心臟功能和生活质量。 技术进步、意识增强和老年人口增加等因素正在推动市场扩张。 此外,有利的报销政策和持续的研发活动预计也将在未来几年进一步推动市场增长。
儘管预防和治疗取得了进展,但心血管疾病导致的死亡中约有 50% 是由于心源性猝死。 这仍然是一个重要的死亡原因。 心脏病及其危险因素的患病率不断增加,增加了对 CRT 设备的需求。
本报告调查了全球心臟再同步治疗 (CRT) 市场,并提供了市场概况、影响市场的各种因素分析、技术和创新趋势、监管环境以及市场规模趋势和预测。分类和地区、竞争状况、主要公司简介等。
Global Cardiac Resynchronization Therapy Market size was valued at USD 4.06 billion in 2021 and is poised to grow from USD 4.26 billion in 2022 to USD 6.23 billion by 2030, growing at a CAGR of 4.8% in the forecast period (2023-2030).
Cardiac resynchronization therapy (CRT) is a treatment for heart failure patients. The global market for CRT is witnessing significant growth due to the rising prevalence of cardiovascular diseases worldwide. CRT devices help restore synchronized heart contractions, improving cardiac function and quality of life. Factors such as technological advancements, increasing awareness, and the growing geriatric population are driving market expansion. Moreover, favorable reimbursement policies and ongoing research and development activities are expected to further fuel the market's growth in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of Cardiac Resynchronization Therapy and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
Global Cardiac Resynchronization Therapy Market is segmented based on the Type, Application, End User and region. Based on Type Global market is segmented into CRT-Defibrillator and CRT-Pacemaker. Based on the Application into Intraventricular desynchrony, Interventricular (V-V) desynchrony, Atrioventricular (A-V) desynchrony. Based on the End User into Hospitals, Cardiac Care Centres, and Ambulatory Surgical Centres. Based on region, it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
Driver
Despite advancements in prevention and therapy, approximately 50% of deaths caused by cardiovascular diseases are due to sudden cardiac death. This remains a significant cause of mortality. The prevalence of heart diseases and their risk factors is increasing, leading to a higher demand for cardiac resynchronization therapy devices. Heart failure is one of the primary contributors to global mortality.
Restrain
In June 2022, Boston Scientific Corporation initiated a recall for the INGENIO family of pacemakers and CRT-Ps. Some of the affected devices include ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL. These devices were distributed between November 2016 and August 2022, after being manufactured from September 2016 to December 2018. Approximately 48,000 devices were recalled in the United States due to the potential safety mode activation.
Trend
Patients with heart failure who are at a high risk of sudden cardiac death should consider using CRT-Defibrillators (CRT-D). A CRT-D device treats slow heart rhythms like a regular pacemaker, but it also delivers small electrical impulses to the left and right ventricles to facilitate synchronized contractions. This improves the efficiency of heart pumping. Furthermore, CRT-D devices can address arrhythmias, which are rapid and dangerous heartbeats that may lead to sudden cardiac arrest. If the device detects such rapid heartbeats, it delivers a shock to the heart, known as defibrillation, to restore a regular rhythm. Without this life-saving treatment, the rapid pulse can result in death within minutes. These devices offer new opportunities for patient engagement and remote monitoring through smartphone connectivity and connected applications. They are favored by patients due to their user-friendly design, longer battery life, and compatibility with MRI scans. Given the increasing incidence and mortality of cardiovascular diseases, the demand for these devices has recently risen.